Vascular Solutions (NASDAQ:VASC) target price raised to $58.00, reported today by Needham
- Updated: October 5, 2016
Vascular Solutions (NASDAQ:VASC) had its target price raised to $58.00 by Needham in a report released 10/06/2016. The new target price indicates a possible upside of 0.23% based on the company's last stock close price.
Yesterday Vascular Solutions (NASDAQ:VASC) traded -0.88% lower at $47.11. The company’s 50-day moving average is $48.46 and its 200-day moving average is $41.41. The last stock close price is up 13.76% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 104,445 shares of the stock were exchanged, down from an average trading volume of 112,863
See Chart Below
Vascular Solutions has a price-earnings ratio of 87.24 with a one year low of $24.34 and a one year high of $50.72 Vascular Solutions’s market capitalization is presently $0.
More About Vascular Solutions (NASDAQ:VASC)
Vascular Solutions, Inc. is a medical device company focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company's product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world. Its products include GuideLiner catheters, Pronto catheters, Vein catheter reprocessing, Micro-introducer kits, Hemostatic patches, Radial access products, Langston catheters and D-Stat Flowable hemostat. The Company's product portfolio includes a spectrum of over 90 products consisting of approximately 900 stock keeping units (SKUs) covering an array of blood clotting devices, extraction catheters, access catheters, guide extension catheters, micro-introducer kits, guidewires, snare and retrieval devices, a reprocessing service for radiofrequency catheters and a laser and procedure kits for the treatment of varicose veins.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.